Hitachi to Produce Regenerative Medicines

Hitachi Chemical has joined into an agreement with Daiichi Sankyo and SanBio Group to produce regenerative medicines manufactured by respective companies. On March 19th 2018, Hitachi contracted an agreement with Daiichi Sankyo in order to conduct clinical manufacturing of that company’s regenerative medicines for the Japan market and as well as it signed an agreement on March 13th 2018 with SanBio to produce late stage clinical products and as well as commercial products of SB623 – a proprietary regenerative medicine being produced by SanBio

Leave a Reply

Skip to toolbar